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Introduction: Early diagnosis of and subsequent monitoring of therapy for rheumatoid arthritis (RA) could benefit
from detection of (sub)clinical synovitis. Imaging of (sub)clinical arthritis by targeting the translocator protein (TSPO)
on activated macrophages is feasible using (R)-[11C] PK11195-based positron emission tomography (PET), but clinical
applications are limited by background uptake in peri-articular bone/bone marrow. The purpose of the present
study was to evaluate two other TSPO ligands with potentially lower background uptake in neurological studies,
[11C]DPA-713 and [18F]DPA-714, in a rat model of arthritis.
Methods: TSPO binding of DPA-713, DPA-714 and PK11195 were assessed by in vitro competition studies with [3H]DPA-713
using human macrophage THP-1 cells and CD14+ monocytes from healthy volunteers. In vivo studies were performed in
rats with methylated bovine serum albumin-induced knee arthritis. Immunohistochemistry with anti-TSPO antibody was
performed on paraffin-embedded sections. Rats were imaged with [11C]DPA-713 or [18F]DPA-714 PET, followed by ex vivo
tissue distribution studies. Results were compared with those obtained with the tracer (R)-[11C]PK11195, the established
ligand for TSPO.
Results: In THP-1 cells, relative TSPO binding of DPA-713 and DPA-714 were 7-fold and 25-fold higher, respectively,
than in PK11195. Comparable results were observed in CD14+ monocytes from healthy volunteers. In the arthritis rat
model, immunohistochemistry confirmed the presence of TSPO-positive inflammatory cells in the arthritic knee. PET
images showed that uptake of [11C]DPA-713 and [18F]DPA-714 in arthritic knees was significantly increased compared
with contralateral knees and knees of normal rats. Uptake in arthritic knees could be largely blocked by an excess of
PK11195. [11C]DPA-713 and [18F]DPA-714 provided improved contrast compared with (R)-[11C]PK11195, as was shown
by significantly higher arthritic knee-to-bone ratios of [11C]DPA-713 (1.60 ± 0.31) and [18F]DPA-714 (1.55 ± 0.10)
compared with (R)-[11C]PK11195 (1.14 ± 0.19).
Conclusions: [11C]DPA-713 and [18F]DPA-714 clearly visualized arthritis and exhibited lower (peri-articular) bone/bone
marrow uptake than (R)-[11C]PK11195. These features merit further investigation of these tracers for early diagnosis and
therapy monitoring of RA in a clinical setting.* Correspondence: j.vanderlaken@vumc.nl
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Macrophages play a central role in the pathogenesis of
rheumatoid arthritis (RA) by driving synovial inflammation
and subsequent tissue destruction [1]. Macrophages infil-
trate the synovium early in the course of the disease with
both number and level of macrophage activation correlat-
ing with clinical disease activity [2]. Visualization of synovial
macrophages using specific positron emission tomography
(PET) tracers could, therefore, offer the possibility of both
early diagnosis [3] and sensitive monitoring of disease [4].
The translocator protein (TSPO, formerly known as the
peripheral benzodiazepine receptor) is primarily localized
in the outer mitochondrial membrane, where it has a
function in cholesterol transport as a rate-limiting step in
steroid biosynthesis [5]. Increased TSPO expression has
been associated with an activated state of macrophages
and microglia [6], based on which TSPO has been recog-
nized as a biomarker for inflammatory diseases [7].
The prototypical radioligand for PET imaging of the
TSPO is (R)-[11C]PK11195 (1-[2-chlorophenyl]-N-methyl-
N-[1-methyl-propyl]-3-isoquinoline carboxamide) [8]. Re-
cent studies have demonstrated that, although imaging of
clinical and subclinical arthritis with (R)-[11C]PK11195
PET is promising, considerable background uptake of the
tracer in peri-articular tissues (in particular bone/bone
marrow) may hamper detection of subtle changes in
macrophage infiltration and inflammation [3,9].
Previous (R)-[11C]PK11195 studies in neuroinflammation
have shown a relatively low specific-to-nonspecific ratio,
possibly due to its high lipophilicity and low bioavailability
[10]. This has initiated research in developing next
generation TSPO tracers that exhibit higher binding
affinities and better specific-to-nonspecific binding ra-
tios than (R)-[11C]PK11195 [11]. Two candidate com-
pounds that meet this profile include [11C]DPA-713
(N,N-diethyl-2-(4-methoxyphenyl)-5,7-dimethylpyrazolo
[1,5-a]pyrimidine-3-acetamide) and [18F]DPA-714 (N,N-
diethyl-2-(2-[4-(2-fluoroethoxy)-phenyl]-5,7-dimethylpyrazolo
[1,5-a]pyrimidin-3-yl)-acetamide) [12-14].
The potential of the DPA tracers for PET imaging of
RA has not yet been reported. Therefore, the aim of this
study was to evaluate [11C]DPA-713 and [18F]DPA-714
as novel candidate PET tracers in a rat model of RA,
using a direct comparison to (R)-[11C]PK11195.
Methods
Synthesis of (R)-[11C]PK11195, [11C]DPA-713, [18F]DPA-714
and [3H]DPA-713
(R)-[11C]PK11195 was synthesized routinely with a radio-
chemical purity >98%, and a mean specific activity of 95.7 ±
28.4 GBq/μmole [15]. [11C]DPA-713 and [18F]DPA-714 were
synthesized routinely with a radiochemical purity of >98%
and >95% and a specific activity of >40 GBq/μmole and
>75 GBq/μmole, respectively. One [11C]DPA-713 synthesisyielded a specific activity of 1.5 GBq/μmole, however, this
did not affect in vivo results.
[3H]DPA-713 was synthesized with a radiochemical pur-
ity of 99.8% and a specific activity of 2.37 GBq/μmole. For
a detailed description of [11C]DPA-713, [18F]DPA-714 and
[3H]DPA-713 synthesis see Additional file 1.
In vitro binding competition assay
In vitro TSPO binding competition assays were performed
using the human monocytic-macrophage cell line THP-1,
which expresses high TSPO levels [16] and freshly isolated
human monocytes. THP-1 cells were grown in RPMI-
1640 medium supplemented with 10% fetal calf serum,
2 mM L-glutamine and 100 μg/mL penicillin/strepto-
mycin. Cells were harvested in the mid-log phase of
growth and washed twice in ice-cold Hepes-buffered sa-
line solution (pH 7.4) supplemented with 0.1% (w/v) BSA
and finally resuspended in this buffer to a density of 1 ×
106 cells/mL. Next, 1 mL of this cell suspension was incu-
bated in an Eppendorf tube with 10 pmol [3H]DPA-713 in
the absence or presence of a 0.25- to 100-fold molar ex-
cess of unlabelled PK11195 (Sigma Aldrich Chemie BV,
Zwijndrecht, The Netherlands), DPA-713 or DPA-714
(provided by M. Kassiou). Peripheral blood mononuclear
cells were isolated from healthy volunteers by Ficoll density
gradient centrifugation. CD14+ monocytes were positively
selected with magnetic-activated cell sorting (MACS) mag-
netic beads (Miltenyi Biotec, Bergisch Gladbach, Germany)
according to the manufacturer’s protocol. One mL of 106
CD14+ cells were incubated with 10 pmol [3H]DPA-713 in
the absence or presence of 20 or 50 pmol unlabelled
PK11195, DPA-713 or DPA-714.
Following 30 minutes incubation at 4°C, THP-1 cells or
CD14+ monocytes were centrifuged for one minute in an
Eppendorf centrifuge (1,200 rpm). The supernatant was aspi-
rated and the remaining fluid removed by cotton swabs.
The cell pellet was then resuspended in 200 μL of H2O
and transferred to a scintillation vial containing 5 mL Opti-
Fluor (PerkinElmer, Waltham, Massachusetts, USA) scintilla-
tion fluid. The cell-associated amount of [3H]DPA-713 was
assessed with a liquid scintillation analyzer (Tri-Carb 2800TR,
PerkinElmer, Waltham, Massachusetts, USA). Samples
containing a 1,000-fold molar excess of unlabelled PK11195
served as controls for specificity. Ethical approval was obtained
from the ethics committee of the VU University Medical Cen-
ter and informed consent was given by all healthy controls.
Animals
Male Wistar rats (body weight approximately 200 to
300 g, Charles River International Inc, Sulzfeld, Germany)
were fed with standard food (16% protein rodent diet,
Harlan Laboratories Inc., Madison, WI, USA) and water
ad libitum. Rats were housed in groups of four in standard
laboratory cages and kept in an air-conditioned room at a
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about 50% and under a 12 hour light/12 hour dark cycle.
Arthritic rats were scanned with (R)-[11C]PK11195 (n = 5),
[11C]DPA-713 (n = 7) or [18F]DPA-714 (n = 6), which was
followed by tissue distribution (n = 5, 7, 5, respectively).
Two arthritic rats per tracer were used for TSPO binding
blocking studies (that is, PET scanning and tissue distribu-
tion) with [11C]DPA-713 and [18F]DPA-714, and un-
labelled PK11195. In addition, five normal (untreated) rats
per tracer were used for tissue distribution studies with
[11C]DPA-713 and [18F]DPA-714. Animal experiments
were performed in accordance with the Dutch law on ani-
mal experimentation and the protocol was approved by
the committee on animal experimentation of the VU Uni-
versity Medical Center.
Induction of knee arthritis
Antigen-induced arthritis was elicited as described pre-
viously, but with some adaptations for optimal PET im-
aging of arthritis [17-20]. Subcutaneous immunization
was performed at days 0 and 7 with 200 μL of a solution
containing 50 mg mBSA (Sigma-Aldrich Chemie BV,
Zwijndrecht, The Netherlands) dissolved in 1 mL 0.9%
NaCl and emulsified in 1 mL complete Freund’s adju-
vant (Sigma-Aldrich, Steinheim, Germany) and 1 mL
(1011 particles) custom Bordetella pertussis antigen (Becton
Dickinson, Breda, The Netherlands). Induction of mono-
arthritis was achieved at day 20 by an intra-articular injec-
tion in the right knee with 60 μL of a solution of 10 mg
mBSA in 1 mL 0.9% NaCl. At day 27, PET scans were per-
formed, after which rats were sacrificed immediately for
analysis of ex vivo tissue distribution of the tracers.
Histopathology and immunohistochemistry
Both knees were dissected in toto and fixed (10% parafor-
maldehyde, 2% sucrose/phosphate buffered saline, pH 7.3)
for seven days at 4°C. Bone tissue of the knees was decalci-
fied for approximately seven weeks at 4°C in a solution
with 123 mM sodium ethylenediaminetetraacetic acid
(Na2-EDTA.2H2O, Merck, Darmstadt, Germany) (pH 7.2)
and 113 nM NaOH (Sigma-Aldrich Chemie BV). The de-
calcification solution was regularly refreshed. After decal-
cification, knees were rinsed and processed for paraffin
embedding. Sagittal sections (5 μm) from the center of the
joint were used for immunohistochemical staining for the
TSPO receptor using the rabbit anti-TSPO polyclonal anti-
body NP115 (kindly provided by Prof. Higuchi, National In-
stitute of Radiological Sciences, Chiba, Japan) [21]. The
immunohistochemical procedure was performed as fol-
lows: sections were deparaffinized and autoclaved for five
minutes at 121°C in 0.01 M citrate buffer (pH 6.0) for
antigen retrieval. This was followed by incubation with
0.3% H2O2 in methanol for 30 minutes at room
temperature and overnight incubation at 4°C with 1:1,500diluted NP155. Sections were washed extensively with a buf-
fer containing 0.1 M Tris–HCl (pH 7.5), 0.15 M NaCl and
0.05% Tween20 before incubation with the secondary anti-
body (swine anti-rabbit, (DAKO, Glostrup, Denmark) E0353,
1:300 diluted) for 30 minutes at room temperature. Finally,
the Vectastain ABC kit (Vector Laboratories, Burlingame,
CA, USA) was used according to the manufacturer’s instruc-
tions. Peroxidase activity was detected using a solution of
3.3′-diaminobenzidine tetrahydrochloride containing 0.01%
H2O2. Subsequently, sections were counterstained with
hematoxylin, dehydrated and mounted. Negative controls
were included by replacement of the primary antibody
with 1% BSA/PBS. A Leica 4000B microscope and Leica
digital camera DC500 (Microsystems B.V., Rijswijk, The
Netherlands) were used to capture images.
PET scanning protocol
Scanning was performed using a LSO/LYSO double layer
ECAT High Resolution Research Tomograph (HRRT, CTI/
Siemens, Knoxville, TN, USA): a small animal and human
brain three-dimensional scanner with high spatial reso-
lution (2.3 to 3.4 mm full width at half maximum) and high
sensitivity [22]. Rats were anesthetized (approximately 2%
isofluran with an oxygen flow of 0.6 to 0.8 L/min) before
positioning in the HRRT. A static transmission scan (six mi-
nutes) using a rotating 740 MBq 137Cs point source was per-
formed. A one hour emission scan was started at intravenous
injection of 10.5 ± 2.9 MBq (R)-[11C]PK11195, 17.0 ± 3.7 MBq
[11C]DPA-713 or 14.5 ± 3.7 MBq [18F]DPA-714 via a jugular
vein canula. PET data were normalized and corrected for scat-
ter, randoms, attenuation, decay and dead time and con-
verted into 16 sinograms (5 × 5, 5 × 10, 3 × 15, 2 × 30,
2 × 60, 2 × 150, 2 × 300, 1 × 600, 2 × 900 s). Images were re-
constructed using an iterative three-dimensional ordered
subset expectation maximization (OSEM) with eight itera-
tions and sixteen subsets. Resulting images had a matrix
size of 256 × 256 × 207 voxels, each with a dimension of
1.21 × 1.21 × 1.21 mm3.
PET image analysis
PET images were analyzed using AMIDE software
(Amide’s a Medical Image Data Examiner, version 0.9.2)
[23]. Fixed size ellipsoidal shaped regions of interest (ROI)
(dimensions: 6.0 × 17.7 × 7.4 mm3) were manually drawn
over the area of the left and right knees in the last frame
of the image. ROIs were projected onto the dynamic
image sequence, and time-activity curve (TAC) data were
extracted. TACs were expressed as standardized uptake
values (SUV): mean ROI radioactivity concentration nor-
malized for injected dose and body weight. Uptake of (R)-
[11C]PK11195, [11C]DPA-713 and [18F]DPA-714 in both
knees was determined by averaging the SUV values
obtained over the period from 50 to 60 minutes post-
injection.
Gent et al. Arthritis Research & Therapy 2014, 16:R70 Page 4 of 9
http://arthritis-research.com/content/16/2/R70Ex vivo tissue distribution studies
Immediately after each scan, that is, 60 minutes after
intravenous injection of (R)-[11C]PK11195, [11C]DPA-
713 or [18F]DPA-714, heart puncture of anesthetized rats
was performed to collect blood samples. Next, rats were
sacrificed by cervical dislocation, which was followed by
excision and weighing of both knees (in toto), bone ob-
tained from the right hind leg and tissue from various
internal organs. Radioactivity present in blood and tis-
sues (in percentage injected dose per gram of tissue: %
ID/g) was determined using an LKB 1282 Compugamma
CS gamma counter (LKB Wallac, Turku, Finland).
In vivo blocking of TSPO binding
Tracer binding was investigated to verify that binding to
the inflamed synovium was mediated through TSPO. To
this end, blocking studies were performed in arthritic rats
by pre-administration of 5 mg/kg unlabelled PK11195
(Sigma Aldrich Chemie BV) five minutes prior to the injec-
tion of [11C]DPA-713 or [18F]DPA-714. PET and ex vivo tis-
sue distribution studies were performed as described above.
Statistical analysis
Statistical tests were performed using IBM SPSS Statistics
20 (IBM, Armonk, NY, USA). A Wilcoxon signed rank
(exact) test was used to determine differences in paired
observations, for example, uptake of (R)-[11C]PK11195,
[11C]DPA-713 or [18F]DPA-714 in arthritic versus contra-
lateral knees. Mann–Whitney (exact) tests were performed
to analyze differences in (R)-[11C]PK11195, [11C]DPA-713
or [18F]DPA-714 uptake in arthritic versus normal knees.
Kruskal-Wallis (exact) tests were performed to determine
differences between (R)-[11C]PK11195, [11C]DPA-713 and
[18F]DPA-714 absolute uptake and tissue uptake ratios.
If significance was found, Mann–Whitney (exact) tests
with Bonferroni correction were used as post-hoc tests.
Results are presented as mean ± standard deviation (SD)
unless stated otherwise. P-values <0.05 were considered
statistically significant.Results
In vitro TSPO competition assay
Figure 1 shows displacement of [3H]DPA-713 from TSPO
in the presence of increasing concentrations of unlabelled
DPA-713, DPA-714 and PK11195. In THP-1 cells it was
demonstrated that for 50% displacement of [3H]DPA-713
binding to TSPO, 7-fold lower concentrations of DPA-713
and 25-fold lower concentrations of DPA-714 were
needed compared with PK11195 (Figure 1A). Comparable
results with the same ranking were observed in freshly iso-
lated human CD14+ monocytes (Figure 1B). Thus, DPA-
714 and DPA-713 showed higher relative binding com-
pared with that of PK11195.Presence of synovial TSPO-positive cells in arthritic knees
Intra-articular injection of mBSA in the right knees of im-
munized rats provoked development of arthritis which
was characterized by an influx of TSPO-positive cells in
the synovium as shown by immunohistochemical staining
(Figure 2B). Based on cell morphology, TSPO-positive
cells were largely recognized as macrophages and neutro-
phils. In contrast, in the contralateral control knee only
limited numbers of TSPO-positive cells were present
(Figure 2C).
PET studies
All three TSPO tracers clearly accumulated in arthritic
knees (Figure 3A-C). Mean absolute uptake (in SUV) of
[11C]DPA-713 and [18F]DPA-714 in arthritic knees was
markedly higher than in contralateral knees (2.37 ± 0.28
versus 1.26 ± 0.16, P = 0.02; 1.74 ± 0.46 versus 1.08 ± 0.19,
P = 0.06, respectively) (Figure 3B,C). For comparison, uptake
values (in SUV) of (R)-[11C]PK11195 in arthritic and contra-
lateral knees were 2.32 ± 0.31 and 1.39 ± 0.17, respectively
(Figure 3A). Knee TAC of arthritic and contralateral knees
showed that increased [11C]DPA-713, [18F]DPA-714 and
(R)-[11C]PK11195 uptake in the arthritic knee was evident
almost immediately after intravenous injection of the
tracer and persisted for at least one hour (Figure 3D-F).
This resulted in stable arthritic-to-contralateral knee
ratios over time. Increased (R)-[11C]PK11195, [11C]DPA-713
and [18F]DPA-714 uptake was further noticed in bone
(marrow), heart, lung, spleen, kidney and intestine (see
Additional file 2: Figure S2) [24].
Ex vivo tissue distribution and blocking studies
[11C]DPA-713 and [18F]DPA-714 uptake (expressed as
mean %ID/g) in arthritic knees was significantly higher than
in contralateral knees (0.70 ± 0.14 versus 0.47 ± 0.07, P =
0.02; 0.68 ± 0.06 versus 0.45 ± 0.03, P= 0.03, respectively)
(Figure 4) and normal knees (0.52 ± 0.05, P= 0.05; 0.47 ±
0.03, P= 0.004, respectively). Absolute joint uptake in arth-
ritic and contralateral knees of both DPA tracers was com-
parable with that of (R)-[11C]PK11195 in arthritic (0.78 ±
0.05) and contralateral (0.57 ± 0.05) joints. Consistently, mean
arthritic-to-contralateral knee uptake ratios of [11C]DPA-713
(1.49 ± 0.08) and [18F]DPA-714 (1.40 ± 0.30) were similar to
that of (R)-[11C]PK11195 (1.40 ± 0.10).
In previous studies in RA patients, background uptake of
(R)-[11C]PK11195 in peri-articular bone/bone marrow was
shown, which potentially hampered the evaluation of subtle
joint uptake [3]. Therefore, we examined bone uptake of
[11C]DPA-713 and [18F]DPA-714 in the present study and
calculated arthritic knee-to-bone ratios. Significantly higher
uptake in bone was found for (R)-[11C]PK11195 than for
[11C]DPA-713 and [18F]DPA-714 (Figure 5A). Conse-
quently, arthritic knee-to-bone ratios of [11C]DPA-713
and [18F]DPA-714 were significantly higher than that of
Figure 1 [3H]DPA-713 TSPO binding competition studies. (A) Displacement of [3H]DPA-713 TSPO binding by PK11195, DPA-713 and DPA-714 in
human THP-1 cells. Cells were incubated with 10 nM [3H]DPA-713 in the presence of increasing concentrations of unlabelled PK11195, DPA-713 and
DPA-714. Fifty percent displacement of [3H]DPA-713 was observed at 128 nM PK11195, 18.5 nM DPA-713, and 5.2 nM DPA-714. Results are presented
as mean ± SEM of three separate experiments. (B) [3H]DPA-713 binding competition by unlabelled PK11195, DPA713 and DPA714 in CD14+ monocytes
from healthy volunteers. Assay conditions were that 1 mL of 106 CD14+ cells were incubated with 10 pmol [3H]DPA-713 in the absence or presence of
20 or 50 pmol unlabelled PK11195, DPA-713 or DPA-714. Residual binding of [3H]DPA-713 under these conditions is depicted. Addition of excess
(2,000-fold molar excess) DPA-713 resulted in almost complete displacement of [3H]DPA-713 (that is, 0.3 ± 0.2% residual binding, results not shown).
Mean [3H]DPA-713 binding capacity was 2.6 pmol/106 CD14+ cells (range 1.3 to 5.1). Results are presented as mean ± SEM of three separate
experiments. SEM, standard error of the mean; TSPO, translocator protein.
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tissue distribution showed accumulation of all TSPO tracers
in heart, lung, spleen, kidney and intestine (Figure 4).
Blocking of TSPO binding by pre-administration of un-
labelled PK11195 largely abolished uptake of [11C]DPA-713
and [18F]DPA-714 in these tissues as shown in PET and by
tissue distribution studies (see Additional file 2: Figure S2
and Figure 4, respectively). With respect to arthritic knees,Figure 2 Immunohistochemical staining for macrophages and TSPO.
represents the region of the synovium as shown in panels B and D (magn
color) in arthritic knee (magnification, 200x). (C) Immunohistochemical stain
Arrows indicate the synovial lining in which the TSPO-positive cells reside.
200x). TSPO, translocator protein.mean [11C]DPA-713 and [18F]DPA-714 uptake (in %ID/
gram) in the arthritic knee was five-fold (0.14 ± 0.04) and
three-fold (0.23 ± 0.06) decreased, respectively, after block-
ing (Figure 4).
Discussion
In this study, the potential of the two high affinity TSPO
PET tracers [11C]DPA-713 and [18F]DPA-714 for imaging(A) Hematoxylin and eosin staining of an arthritic knee. The square
ification, 25x) (B) Immunohistochemical staining for TSPO (brown
ing for TSPO (brown color) in contralateral knee (magnification, 200x).






































Figure 3 [11C]DPA-713, [18F]DPA-714 and (R)-[11C]PK11195 PET images and corresponding TAC of arthritic and contralateral knees.
Representative examples of [11C]DPA-713, [18F]DPA-714 and (R)-[11C]PK11195 images at the level of the knees (A-C) with corresponding TAC of
arthritic and contralateral knees (D-F). Results are presented as mean ± SD of seven, five and five arthritic rats for [11C]DPA-713, [18F]DPA-714 and
(R)-[11C]PK11195, respectively. R = right arthritic knee. PET, positron emission tomography; SD, standard deviation; TAC, time-activity curve.
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mBSA-induced rat model of RA.
In vitro binding competition studies confirmed high
(relative) binding of both [11C]DPA-713 and [18F]DPA-714
to TSPO. Furthermore, both DPA tracers showed high up-
take in arthritic knee joints of rats as shown by both in vivo
PET scans and ex vivo tissue distribution studies. Uptake in
arthritic joints was, at least for a large part, specific, as it
was reduced significantly following pre-treatment with anexcess of PK11195. Finally, compared with (R)-[11C]PK11195,
bone/bone marrow uptake of both DPA tracers was signifi-
cantly lower, providing enhanced contrast.
Previous studies have shown higher binding affinities of
DPA-713 and DPA-714 to TSPO than PK11195 using rat
kidney membrane binding assays [13]. In the present
study, TSPO binding of DPA-713 and DPA-714 was com-
pared with that of PK11195 using competition binding
studies with [3H]DPA-713 in viable human monocytic/
Figure 4 Tissue distribution of [11C]DPA-713 and [18F]DPA-714 with and without blocking of TSPO binding with unlabelled PK11195.
Tissue distribution of (A) [11C]DPA-713 and (B) [18F]DPA-714 in arthritic rats with (grey bars) and without (black bars) blocking of TSPO binding
with 5 mg/kg unlabelled PK11195. Results are presented as mean ± SD of seven arthritic rats for [11C]DPA-713, six arthritic rats for [18F]DPA-714
and two arthritic rats per tracer for blocking experiments. SD, standard deviation; TSPO, translocator protein.
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model for in vivo macrophages. These studies confirmed
increased binding affinities of the DPA tracers compared
with PK11195.
PET studies with [11C]DPA-713 and [18F]DPA-714 in rat
models of neuroinflammation have shown reduced non-
specific binding in comparison with (R)-[11C]PK11195,
which would facilitate better detection of mild inflamma-
tion [25,26]. For imaging of RA, uptake of the tracer in the
inflamed synovium in relation to uptake in surrounding
bone and bone marrow is the most important parameter,
as the latter may mask subtle uptake in the synovium and
can prohibit its precise quantification. In fact, Kam et al.
[27] showed TSPO expression in rodent bone tissue.
In addition, dosimetry studies of (R)-[11C]PK11195 and
[11C]DPA-713 showed uptake in human red marrow[28,29]. Therefore, prevention of uptake of TSPO tracers
in peri-articular bone of joints affected by RA does not
seem to be feasible. Nevertheless, in the present study,
both [11C]DPA-713 and [18F]DPA-714 showed excellent
uptake in mBSA-induced arthritis in rats and exhibited
markedly lower uptake in peri-articular bone/bone mar-
row than (R)-[11C]PK11195. This offers new opportunities
for detection of more subtle (sub)clinical arthritis, which
is relevant for early diagnosis and therapy monitoring of
RA. Future studies should demonstrate whether this holds
true for imaging of arthritis in RA patients.
The mBSA-induced rat arthritis model is a widely used
model of RA because of its resemblance to human RA
pathology at the joint level [17,19,20]. Immunohistochemi-
cal studies demonstrated the presence of abundant num-
bers of TSPO-positive macrophages and neutrophils in the
Figure 5 (R)-[11C]PK11195, [11C]DPA-713 and [18F]DPA-714 bone uptake. Absolute uptake (A) and arthritic knee-to-bone ratios (B) of [11C]
DPA-713 (dark grey bars) and [18F]DPA-714 (light grey bars) compared with that of (R)-[11C]PK11195 (black bars) obtained from ex vivo tissue
distribution studies. Results are presented as mean ± SD of five arthritic rats for (R)-[11C]PK11195, seven arthritic rats for [11C]DPA-713 and six
arthritic rats for [18F]DPA-714. SD, standard deviation.
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do not solely target macrophages, but rather the mixed cel-
lular influx in the arthritic knee, reminiscent of human RA.
Unfortunately, the small size of the (arthritic) rat knee
joint and small volume of (inflamed) synovium hampers
exact determination of tracer uptake in synovial tissue. For
this reason, analysis of tracer uptake in PET scans was per-
formed by manually drawing ROIs on top of the whole knee
region, because a ROI covering only synovial tissue was not
feasible due to insufficient spatial resolution. For determin-
ation of ex vivo tissue distribution, radioactivity present in
the knee joint as a whole, including not only synovium but
also peri-articular tissues, was measured. Consequently,
both absolute tracer uptake in synovium and arthritic knee-
to-bone ratios may have been underestimated.
Finally, for future clinical [11C]DPA-713 and [18F]DPA-
714 studies in RA patients, screening for TSPO genetic
polymorphism will be important. As previously has been
shown in human brain studies, genetic polymorphism in
the TSPO gene causes differences in binding affinity of all
TSPO ligands that are in current clinical use, except (R)-
[11C]PK11195 [30,31]. Therefore, knowledge of patient
binding status will be essential for correct quantification
of TSPO expression in arthritic joints with PET.
Conclusions
The two new generation TSPO ligands DPA-713 and DPA-
714 showed significantly higher relative binding to TSPO
compared to the established TSPO ligand PK11195 in
in vitro studies. In vivo, [11C]DPA-713 and [18F]DPA-714
proved to be promising radioligands for targeting arthritis
in an mBSA-induced arthritis model in rats. While absolute
uptake of both tracers in inflamed joints was comparable
to that of (R)-[11C]PK11195, background uptake in bone
tissue was significantly lower, potentially providing im-
proved target-to-background contrast on PET images.Additional files
Additional file 1: Synthesis of [11C]DPA-713, [18F]DPA-714 and [3H]
DPA-713. Detailed synthesis protocols of [11C]DPA-713, [18F]DPA-714 and
[3H]DPA-713 including reaction schemes.
Additional file 2: Figure S2. [11C]DPA-713 and [18F]DPA-714 PET
images with and without blocking of TSPO binding with unlabelled
PK11195. Representative [11C]DPA-713 (A) and [18F]DPA-714 (B) PET
images of arthritic rats without (left) and with (right) blocking of TSPO
binding with PK11195. SUV = standardized uptake value.
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